vs
Side-by-side financial comparison of Hologic (HOLX) and VISHAY INTERTECHNOLOGY INC (VSH). Click either name above to swap in a different company.
Hologic is the larger business by last-quarter revenue ($1.0B vs $839.2M, roughly 1.2× VISHAY INTERTECHNOLOGY INC). Hologic runs the higher net margin — 17.1% vs 0.9%, a 16.2% gap on every dollar of revenue. On growth, VISHAY INTERTECHNOLOGY INC posted the faster year-over-year revenue change (17.3% vs 2.5%). Over the past eight quarters, VISHAY INTERTECHNOLOGY INC's revenue compounded faster (6.4% CAGR vs 1.5%).
Hologic, Inc. is an American medical technology company primarily focused on women's health; it sells medical devices for diagnostics, surgery, and medical imaging.
Vishay Intertechnology, Inc. is an American manufacturer of discrete semiconductors and passive electronic components founded by Polish-born businessman Felix Zandman. Vishay has manufacturing plants in Israel, Asia, Europe, and the Americas where it produces rectifiers, diodes, MOSFETs, optoelectronics, selected integrated circuits, resistors, capacitors, and inductors. Vishay Intertechnology revenues for 2024 were $2.9 billion. At the end of 2024, Vishay had approximately 22,700 full-time e...
HOLX vs VSH — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0B | $839.2M |
| Net Profit | $179.1M | $7.2M |
| Gross Margin | 56.0% | 21.0% |
| Operating Margin | 22.6% | 2.6% |
| Net Margin | 17.1% | 0.9% |
| Revenue YoY | 2.5% | 17.3% |
| Net Profit YoY | -10.9% | 626.6% |
| EPS (diluted) | $0.79 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $839.2M | ||
| Q4 25 | $1.0B | $800.9M | ||
| Q3 25 | $1.0B | $790.6M | ||
| Q2 25 | $1.0B | $762.3M | ||
| Q1 25 | $1.0B | $715.2M | ||
| Q4 24 | $1.0B | $714.7M | ||
| Q3 24 | $988.0M | $735.4M | ||
| Q2 24 | $1.0B | $741.2M |
| Q1 26 | — | $7.2M | ||
| Q4 25 | $179.1M | $986.0K | ||
| Q3 25 | $187.2M | $-7.9M | ||
| Q2 25 | $194.9M | $2.0M | ||
| Q1 25 | $-17.4M | $-4.1M | ||
| Q4 24 | $201.0M | $-66.1M | ||
| Q3 24 | $178.6M | $-19.3M | ||
| Q2 24 | $194.5M | $23.5M |
| Q1 26 | — | 21.0% | ||
| Q4 25 | 56.0% | 19.6% | ||
| Q3 25 | 55.6% | 19.5% | ||
| Q2 25 | 56.3% | 19.5% | ||
| Q1 25 | 37.5% | 19.0% | ||
| Q4 24 | 56.8% | 19.9% | ||
| Q3 24 | 56.4% | 20.5% | ||
| Q2 24 | 55.4% | 22.0% |
| Q1 26 | — | 2.6% | ||
| Q4 25 | 22.6% | 1.8% | ||
| Q3 25 | 22.6% | 2.4% | ||
| Q2 25 | 24.9% | 2.9% | ||
| Q1 25 | -0.7% | 0.1% | ||
| Q4 24 | 22.5% | -7.9% | ||
| Q3 24 | 23.3% | -2.5% | ||
| Q2 24 | 24.1% | 5.1% |
| Q1 26 | — | 0.9% | ||
| Q4 25 | 17.1% | 0.1% | ||
| Q3 25 | 17.8% | -1.0% | ||
| Q2 25 | 19.0% | 0.3% | ||
| Q1 25 | -1.7% | -0.6% | ||
| Q4 24 | 19.7% | -9.2% | ||
| Q3 24 | 18.1% | -2.6% | ||
| Q2 24 | 19.2% | 3.2% |
| Q1 26 | — | $0.05 | ||
| Q4 25 | $0.79 | $0.01 | ||
| Q3 25 | $0.84 | $-0.06 | ||
| Q2 25 | $0.86 | $0.01 | ||
| Q1 25 | $-0.08 | $-0.03 | ||
| Q4 24 | $0.87 | $-0.48 | ||
| Q3 24 | $0.75 | $-0.14 | ||
| Q2 24 | $0.82 | $0.17 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.4B | $479.5M |
| Total DebtLower is stronger | $2.5B | $983.1M |
| Stockholders' EquityBook value | $5.2B | $2.1B |
| Total Assets | $9.2B | $4.3B |
| Debt / EquityLower = less leverage | 0.48× | 0.47× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $479.5M | ||
| Q4 25 | $2.4B | $515.0M | ||
| Q3 25 | $2.2B | $443.9M | ||
| Q2 25 | $1.9B | $473.9M | ||
| Q1 25 | $1.6B | $609.4M | ||
| Q4 24 | $2.0B | $590.3M | ||
| Q3 24 | $2.3B | $643.8M | ||
| Q2 24 | $2.4B | $672.7M |
| Q1 26 | — | $983.1M | ||
| Q4 25 | $2.5B | $950.9M | ||
| Q3 25 | $2.5B | $919.7M | ||
| Q2 25 | $2.5B | $914.5M | ||
| Q1 25 | $2.5B | $988.2M | ||
| Q4 24 | $2.5B | $905.0M | ||
| Q3 24 | $2.5B | $820.8M | ||
| Q2 24 | $2.5B | $820.6M |
| Q1 26 | — | $2.1B | ||
| Q4 25 | $5.2B | $2.1B | ||
| Q3 25 | $5.0B | $2.1B | ||
| Q2 25 | $4.8B | $2.1B | ||
| Q1 25 | $4.6B | $2.0B | ||
| Q4 24 | $4.8B | $2.0B | ||
| Q3 24 | $5.1B | $2.2B | ||
| Q2 24 | $5.0B | $2.2B |
| Q1 26 | — | $4.3B | ||
| Q4 25 | $9.2B | $4.2B | ||
| Q3 25 | $9.0B | $4.2B | ||
| Q2 25 | $8.8B | $4.2B | ||
| Q1 25 | $8.5B | $4.2B | ||
| Q4 24 | $8.7B | $4.1B | ||
| Q3 24 | $9.2B | $4.2B | ||
| Q2 24 | $8.9B | $4.2B |
| Q1 26 | — | 0.47× | ||
| Q4 25 | 0.48× | 0.46× | ||
| Q3 25 | 0.50× | 0.44× | ||
| Q2 25 | 0.52× | 0.44× | ||
| Q1 25 | 0.55× | 0.49× | ||
| Q4 24 | 0.53× | 0.45× | ||
| Q3 24 | 0.49× | 0.38× | ||
| Q2 24 | 0.51× | 0.38× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $229.9M | $63.7M |
| Free Cash FlowOCF − Capex | $215.2M | — |
| FCF MarginFCF / Revenue | 20.5% | — |
| Capex IntensityCapex / Revenue | 1.4% | — |
| Cash ConversionOCF / Net Profit | 1.28× | 8.89× |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $63.7M | ||
| Q4 25 | $229.9M | $149.4M | ||
| Q3 25 | $355.1M | $27.6M | ||
| Q2 25 | $343.3M | $-8.8M | ||
| Q1 25 | $169.4M | $16.1M | ||
| Q4 24 | $189.3M | $67.7M | ||
| Q3 24 | $367.0M | $50.6M | ||
| Q2 24 | $405.8M | $-24.7M |
| Q1 26 | — | — | ||
| Q4 25 | $215.2M | $54.6M | ||
| Q3 25 | $341.4M | $-24.7M | ||
| Q2 25 | $330.5M | $-73.4M | ||
| Q1 25 | $153.9M | $-45.5M | ||
| Q4 24 | $172.5M | $-77.2M | ||
| Q3 24 | $350.6M | $-9.0M | ||
| Q2 24 | $385.3M | $-87.3M |
| Q1 26 | — | — | ||
| Q4 25 | 20.5% | 6.8% | ||
| Q3 25 | 32.5% | -3.1% | ||
| Q2 25 | 32.3% | -9.6% | ||
| Q1 25 | 15.3% | -6.4% | ||
| Q4 24 | 16.9% | -10.8% | ||
| Q3 24 | 35.5% | -1.2% | ||
| Q2 24 | 38.1% | -11.8% |
| Q1 26 | — | — | ||
| Q4 25 | 1.4% | 11.8% | ||
| Q3 25 | 1.3% | 6.6% | ||
| Q2 25 | 1.3% | 8.5% | ||
| Q1 25 | 1.5% | 8.6% | ||
| Q4 24 | 1.6% | 20.3% | ||
| Q3 24 | 1.7% | 8.1% | ||
| Q2 24 | 2.0% | 8.4% |
| Q1 26 | — | 8.89× | ||
| Q4 25 | 1.28× | 151.48× | ||
| Q3 25 | 1.90× | — | ||
| Q2 25 | 1.76× | -4.39× | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.94× | — | ||
| Q3 24 | 2.05× | — | ||
| Q2 24 | 2.09× | -1.05× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HOLX
| Molecular Diagnostics | $255.3M | 24% |
| Breast Imaging | $219.9M | 21% |
| Services | $216.4M | 21% |
| Capital Equipment Componentsand Software | $187.2M | 18% |
| Cytology Perinatal | $76.0M | 7% |
| Interventional Breast Solutions | $71.2M | 7% |
| Blood Screening | $8.4M | 1% |
| Other Typeof Revenue | $5.4M | 1% |
VSH
Segment breakdown not available.
